- Home
- HQI vs CRVS Comparison
HQI vs CRVS Comparison
Compare HQI & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HQI
- CRVS
- Stock Information
- Founded
- HQI 2002
- CRVS 2014
- Country
- HQI United States
- CRVS United States
- Employees
- HQI N/A
- CRVS N/A
- Industry
- HQI Professional Services
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- HQI Consumer Discretionary
- CRVS Health Care
- Exchange
- HQI Nasdaq
- CRVS Nasdaq
- Market Cap
- HQI 196.4M
- CRVS 516.0M
- IPO Year
- HQI N/A
- CRVS 2016
- Fundamental
- Price
- HQI $13.34
- CRVS $5.10
- Analyst Decision
- HQI Strong Buy
- CRVS Strong Buy
- Analyst Count
- HQI 2
- CRVS 5
- Target Price
- HQI $18.50
- CRVS $12.38
- AVG Volume (30 Days)
- HQI 11.2K
- CRVS 1.7M
- Earning Date
- HQI 11-07-2024
- CRVS 11-12-2024
- Dividend Yield
- HQI 1.83%
- CRVS N/A
- EPS Growth
- HQI N/A
- CRVS N/A
- EPS
- HQI 0.10
- CRVS N/A
- Revenue
- HQI $36,279,000.00
- CRVS N/A
- Revenue This Year
- HQI N/A
- CRVS N/A
- Revenue Next Year
- HQI $8.39
- CRVS N/A
- P/E Ratio
- HQI $134.94
- CRVS N/A
- Revenue Growth
- HQI 0.28
- CRVS N/A
- 52 Week Low
- HQI $11.39
- CRVS $1.30
- 52 Week High
- HQI $15.75
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- HQI 44.71
- CRVS 36.16
- Support Level
- HQI $12.42
- CRVS $4.93
- Resistance Level
- HQI $13.37
- CRVS $6.47
- Average True Range (ATR)
- HQI 0.62
- CRVS 0.40
- MACD
- HQI -0.08
- CRVS 0.06
- Stochastic Oscillator
- HQI 41.44
- CRVS 29.74
About HQI HireQuest Inc. (DE)
HireQuest Inc is a nationwide franchisor of offices providing direct-dispatch, executive search, and commercial staffing solutions in the light industrial and blue-collar segments of the staffing industry and traditional commercial staffing. The company's franchisees provide various types of temporary personnel through two business models operating under the trade names HireQuest Direct, HireQuest, Snelling, DriverQuest, HireQuest Health, Northbound Executive Search, and MRI. The primary source of revenue for the company is royalty fees based on the operation of its franchised offices.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).